FDA approves new blood test for Alzheimer’s disease
A new British partnership pairs a blood test with a cognitive app and national infrastructure to reduce years-long diagnosis waits for Alzheimer patients. The initiative arrives as the United States Food and Drug Administration clears blood tests like Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2 for adults aged forty and older. While these medical tools expand eligible testing populations and permit earlier detection, experts caution that blood screening is not suitable for every patient. Additional research presented at the European College of Neuropsychopharmacology Congress in Munich indicates routine blood panels may also reveal clues about long-term dementia risk.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The US Food and Drug Administration cleared blood tests including Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2 for adults as young as 40.
- ✓ A new British partnership combines a blood test, a cognitive app, and national infrastructure to cut Britain's years-long diagnosis wait.
What changed
A UK partnership now combines a blood test and cognitive app to reduce diagnosis delays.
Live updates
-
UK Partnership Targets Long Alzheimer Diagnosis Delays With Blood Tests
A new British partnership pairs a blood test with a cognitive app and national infrastructure to reduce years-long diagnosis waits for Alzheimer patients. The initiative arrives as the United States Food and Drug Administration clears blood tests like Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2 for adults aged forty and older. While these medical tools expand eligible testing populations and permit earlier detection, experts caution that blood screening is not suitable for every patient. Additional research presented at the European College of Neuropsychopharmacology Congress in Munich indicates routine blood panels may also reveal clues about long-term dementia risk.
Why it matters
Early detection of neurodegenerative conditions allows patients and medical providers to pursue interventions earlier in the disease progression, potentially improving long-term health outcomes. Diagnosis bottlenecks have historically restricted patient access to specialized memory clinics and timely treatment pathways. Integrating blood diagnostics with digital applications aims to streamline clinical workflows across national healthcare systems.
What is confirmed
- The US Food and Drug Administration cleared blood tests including Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2 for adults as young as 40.
- A new British partnership combines a blood test, a cognitive app, and national infrastructure to cut Britain's years-long diagnosis wait.
Still unconfirmed
- Research presented at the ECNP Congress in Munich suggests a common blood test carried out during routine health checks may contain clues about long-term dementia risk.
What to watch next
- Adoption rates of the new UK testing partnership and its effect on diagnosis wait times
- Further clinical validation of routine blood panels for predicting long-term dementia risk
confidence 100%Sources used for this update (7)
- jen.jiji.com — The Philippines to open its embassy in Astana
- Longevity.Technology — UK’s Alzheimer’s diagnosis gap gets a new fix
- medicalxpress.com — How 'people power' and business transformed medicine, but created a whole new set of risks
- medicalxpress.com — Routine blood test may suggest future dementia risk
- jen.jiji.com — Kazakhstan appoints ambassadors to Austria and Pakistan
- www.wral.com — FDA News and Reporting Coverage, page 2 | WRAL
- www.ajmc.com — Neurology | Compendium | AJMC
-
FDA Clears Blood Tests for Alzheimer's Disease
The US FDA has cleared blood tests for Alzheimer's disease, including Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2, for adults as young as 40. These tests support earlier detection and diagnosis, expanding eligible testing populations. Medical experts caution these tests aren't suitable for everyone. The approvals enable earlier detection and treatment, potentially increasing benefits to patients and society.
Why it matters
Alzheimer's disease is a progressive condition, and early detection is crucial for effective treatment. The newly cleared blood tests can help identify Alzheimer's disease before symptoms worsen. According to research, starting Alzheimer's treatment earlier increases benefits to patients and society. The tests will likely have a significant impact on the diagnosis and treatment of Alzheimer's disease.
What is confirmed
- The US FDA has cleared blood tests for Alzheimer's disease, including Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2.
- The tests support earlier detection and diagnosis in adults as young as 40.
- Early detection could help patients start Alzheimer's treatments when they deliver the greatest value to patients, families and society.
- Starting Alzheimer's treatment earlier increases benefits to patients and society.
What to watch next
- Further FDA approvals of Alzheimer's disease tests
- Clinical trial results on the effectiveness of early Alzheimer's treatment
- Guidelines from medical organizations on the use of blood tests for Alzheimer's disease diagnosis
confidence 100%Sources used for this update (7)
- www.fiercepharma.com — Regulatory tracker: GSK's world-first hep B nod; Another Trodelvy approval in EU
- jen.jiji.com — Kazakhstan and Poland discuss new cooperation opportunities
- jen.jiji.com — Superenalotto, 5+1 wins 518 thousand euros: today's winning combination 8 October
- www.eurekalert.org — Starting Alzheimer’s treatment earlier increases benefits to patients and society | EurekAlert!
- jen.jiji.com — XDS Astana’s Malucelli wins opening stage of Tour de Kyushu in Japan
- www.thenationalherald.com — Why Vaccination Protects Your Heart
- medicalxpress.com — Starting Alzheimer's treatment earlier increases benefits to patients and society - Medical Xpress
-
FDA Approves New Blood Test for Alzheimer’s Disease
The US FDA has cleared new blood tests for Alzheimer's disease, including Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2, supporting earlier detection in adults as young as 40. Medical experts caution these tests aren't suitable for everyone. The approvals expand eligible testing populations. These tools enable earlier detection and diagnosis. The tests help identify Alzheimer's disease before symptoms worsen.
Why it matters
Alzheimer's disease is a progressive neurological disorder. Early detection and diagnosis are crucial for effective management and treatment. The new blood tests offer a less invasive and more accessible diagnostic option. The FDA's clearance of these tests reflects growing efforts to improve Alzheimer's diagnosis and care.
What is confirmed
- The FDA cleared Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2 blood tests for Alzheimer's disease.
- These blood tests support earlier detection of Alzheimer's disease in adults as young as 40.
- Medical experts caution that these blood tests are not suitable for everyone.
What to watch next
- Further FDA approvals of Alzheimer's disease diagnostic tests
- Clinical trials evaluating the effectiveness of these blood tests in diverse populations
- Insurance coverage decisions for these new diagnostic tools
confidence 100%Sources used for this update (4)
- www.biopharmadive.com — Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug | BioPharma Dive
- www.wbaltv.com — Women over 50: Never ignore these Alzheimer's signs - WBAL
- Bioengineer.org — Blood Tests That Read the Brain: A Roadmap for Molecular Biomarkers in Stroke Care
- www.mcknightsseniorliving.com — States take action to cover Alzheimer’s diagnostics, treatments
-
FDA Clears Multiple New Alzheimer Blood Tests for Early Detection
The FDA has cleared new blood tests for Alzheimer's disease, including Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2. These tools support earlier detection, with some tests applicable for adults as young as 40. Additionally, the FDA granted breakthrough status to a pTau217 test developed by Roche and Eli Lilly. While these approvals expand the eligible testing population, medical experts caution that these blood tests are not appropriate for everyone.
Why it matters
Earlier reports highlighted social media misinformation promoting asymptomatic screening despite potential harms. The medical community continues to seek better diagnostic tools to bypass systemic hurdles, such as insurance algorithms that flag dementia cases without formal diagnoses.
What is confirmed
- The FDA cleared the PrecivityAD2 blood test from C2N Diagnostics.
- The FDA cleared the Elecsys pTau217 blood test from Roche.
- The FDA granted breakthrough status to a pTau217 blood test developed by Roche and Eli Lilly.
- Some of the new Alzheimer blood tests can be used for adults as young as 40.
Still unconfirmed
- Fujirebio has an FDA-approved blood test for Alzheimer's disease.
- The new blood tests can help identify Alzheimer's earlier.
What to watch next
- Clinical guidelines on which patient populations should receive blood testing
- Updates on the impact of blood tests on insurance algorithm flagging
confidence 90%Sources used for this update (21)
- jen.jiji.com — Kazakhstan appoints new defense minister
- jen.jiji.com — Kazakh servicemen surviving Caspian Sea tragedy awarded Erligi Ushin medal
- medcitynews.com — Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder - MedCity News
- www.medicalnewstoday.com — New FDA-cleared blood tests could help identify Alzheimer’s earlier - MedicalNewsToday
- www.neurologylive.com — From Biomarkers to Prevention: Key Alzheimer Research Stories of 2026 | NeurologyLive - Clinical Neurolog....
- www.ajmc.com — Value-Based Care | Topic | AJMC
- pharmaphorum.com — FDA puts breakthrough tag on Roche, Lilly Alzheimer’s test
- time.com — Who Should Get a Blood Test for Alzheimer's Disease?
- www.neurologylive.com — Marco Meglio | Authors | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
- www.ajmc.com — 5 Notable FDA Approvals From the First Half of September | AJMC
- www.times-standard.com — Good Work | The Walk to End Alzheimer's takes place Oct. 10
- scitechdaily.com — Experimental Drug Reverses Paralysis and Vision Loss in MS-Like Disease
-
Social media promotes Alzheimer's blood tests for asymptomatic patients
Analysis indicates social media posts are promoting Alzheimer's blood tests for people without symptoms while omitting the limitations and potential harms of asymptomatic screening. This occurs as the medical community seeks better diagnostic tools. Previously, researcher Sebastian Palmqvist secured USD 19.4 million from the US National Institutes of Health for diagnostic research. Patients still face systemic hurdles, such as Medigap insurance algorithms flagging Aricept prescriptions as dementia cases even without a formal diagnosis.
Why it matters
Accurate early detection is critical for Alzheimer's treatment but remains difficult outside lab settings. Insurance underwriting processes currently rely on pharmacy records over patient questionnaires.
Still unconfirmed
- Social media posts often omit potential harms and limitations when promoting Alzheimer's blood tests for asymptomatic screening.
What to watch next
- Clinical data on the harms of asymptomatic Alzheimer's screening
- FDA guidance on the marketing of diagnostic blood tests
confidence 70%Sources used for this update (2)
- www.medscape.com — Is Social Media Overselling Alzheimer’s Blood Testing?
- www.drugtargetreview.com — Experimental drug reverses paralysis and vision loss in MS mice
-
Alzheimer's Diagnostic Research Receives Funding Boost
Alzheimer's researcher Sebastian Palmqvist received USD 19.4 million, equivalent to SEK 190 million, from the US National Institutes of Health to advance diagnostic research for the disease. Meanwhile, patients continue to face diagnostic hurdles outside the laboratory. A precautionary prescription for the Alzheimer's medication Aricept can flag a Medigap health insurance application as a dementia case, even when no formal diagnosis exists. This occurs because underwriting algorithms review pharmacy records and can override health questionnaires.
Why it matters
Early detection methods for Alzheimer's disease are expanding alongside growing funding for diagnostic research. However, insurance and underwriting practices create unintended complications for patients navigating preventative care and precautionary medications.
What is confirmed
- Alzheimer's researcher Sebastian Palmqvist has been awarded USD 19.4 million, or SEK 190 million, from the US National Institutes of Health.
- A precautionary prescription for Aricept can flag a Medigap insurance application as a dementia case despite the absence of a diagnosis.
- Underwriting algorithms can override health questionnaires based on pharmacy records.
What to watch next
- Decisions from the FDA regarding the multi-cancer blood test recommended by an advisory panel
- Further developments in Alzheimer's diagnostic research funded by the US National Institutes of Health grant
confidence 100%Sources used for this update (6)
- www.ideastream.org — FDA advisory panel recommends a first: multi-cancer blood test
- www.thenationalherald.com — Grail’s Cancer Blood Test Faces High-Stakes FDA Review
- www.news-medical.net — Experimental drug reverses multiple sclerosis damage in mouse model
- 247wallst.com — Her Doctor Prescribed Aricept “Just in Case” After a Bad Memory Test. The Medigap Underwriter Read the Prescription as Dementia
- medicalxpress.com — Psilocybin may help the brain recover from concussion, new study finds
- www.miragenews.com — SEK 190M Boost for Alzheimer's Diagnostic Research
-
FDA approves Alzheimer's blood test amid clinical trial shortages
The FDA has approved a blood test for Alzheimer's disease, providing a new tool for early detection. However, Alzheimer's Disease International warns that a shortage of clinical trial participants threatens to stall the development of future dementia therapies. This bottleneck persists while researchers explore AI-powered drug discovery and other novel treatments. Current efforts to improve early risk assessment continue, particularly for women, as the medical community seeks to balance new diagnostic capabilities with the need for more therapy volunteers.
Why it matters
Early diagnosis is critical for managing dementia and testing new drugs. A lack of trial participants creates a gap between the ability to detect the disease and the ability to treat it. This tension defines the current state of neurological research.
What is confirmed
- The FDA approved a blood test for Alzheimer's disease.
- Alzheimer's Disease International reports a global shortage of clinical trial participants for dementia therapies.
What to watch next
- Updates on clinical trial recruitment numbers from Alzheimer's Disease International
- Clinical trial results for AI-powered dementia drugs
confidence 100%Sources used for this update (2)
- www.marketscreener.com — Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
- theconversation.com — Psilocybin may help the brain recover from concussion, new study shows
-
Participant Shortage Threatens Alzheimer's Treatment Progress
Alzheimer's Disease International warns that a global shortage of clinical trial participants risks slowing the development of dementia therapies. This challenge arrives as medical research explores new approaches to dementia and AI-powered drug discovery. While the FDA recently approved a blood test for the disease, the lack of trial volunteers creates a bottleneck for future treatments. Meanwhile, the market sees new cognitive supplements and ongoing efforts by figures like Maria Shriver to encourage early risk assessment, particularly among women.
Why it matters
Early detection and treatment are critical for managing cognitive decline. Previous reports highlighted a new FDA-approved blood test and the spread of medical misinformation on social media. The current struggle to recruit trial participants could delay the arrival of next-generation therapies.
What is confirmed
- Alzheimer's Disease International warns that a shortage of trial participants risks slowing progress in dementia therapies.
Still unconfirmed
- Nearly 1 in 3 patients with suspected Lyme disease are co-positive for other tick-borne pathogens according to a Quest Diagnostics study of over 193,000 patients.
What to watch next
- Data on whether recruitment numbers for dementia trials increase following public awareness campaigns
- Clinical results from AI-powered drug discovery initiatives
- Updates on the availability of new dementia drugs via the National Health Service
confidence 90%Sources used for this update (4)
- www.marketscreener.com — Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
- www.usatoday.com — Neura Reviews: Launches Four-Ingredient Daily Capsule Supplement for Cognitive and Memory Wellness in the U.S.
- www.medicalrepublic.com.au — What’s making news in health and medical research
- www.japantimes.co.jp — Clinical trials for Alzheimer’s treatment face global shortage of participants
-
Journalist Maria Shriver Urges Early Alzheimer's Awareness for Women
Journalist and author Maria Shriver is urging individuals, especially women, to consider their risk for Alzheimer's disease long before symptoms appear. Shriver is sharing information regarding how to reduce dementia risk and the personal steps she takes to protect her brain health. This follows federal regulatory approval of a new blood test for Alzheimer's disease and health officials examining the provision of new dementia drugs on the National Health Service. Concurrently, a University of Sydney study revealed that 188 social media posts across Facebook, Instagram, and TikTok, reaching an audience exceeding 114 million followers, spread misleading claims diverging from clinical recommendations.
Why it matters
The push for early awareness intersects with a broader policy and digital environment surrounding Alzheimer's diagnostics. Federal regulators recently approved a new blood test for the disease, expanding diagnostic options as health officials consider new dementia drugs. Meanwhile, researchers have identified sex-specific biological aging clocks linked to Alzheimer progression, and social media platforms are hosting widespread misleading claims that contradict clinical recommendations.
What is confirmed
- Journalist and author Maria Shriver is encouraging people, particularly women, to consider Alzheimer's risk before symptoms appear.
- Federal regulators recently approved a new blood test for Alzheimer disease.
- A University of Sydney study found 188 social media posts across Facebook, Instagram, and TikTok spreading misleading claims about Alzheimer's blood tests.
- Social media posts regarding Alzheimer's blood tests reached a combined audience exceeding 114 million followers.
- Researchers identified sex-specific biological aging clocks linked to Alzheimer progression.
What to watch next
- Decisions by health officials regarding making new dementia drugs available on the National Health Service.
- Further studies tracking the impact of misleading social media claims on clinical recommendations for Alzheimer's blood tests.
confidence 100%Sources used for this update (4)
- www.healthline.com — Think You’re Too Young to Worry About Alzheimer’s? Maria Shriver Says Think Again
- www.omanobserver.om — I lost 3 brothers to cancer. I’m determined not to be next
- inews.co.uk — Burnham told North Sea gas and oil best way to save ‘on the slide’ Britain
- jen.jiji.com — Serie A, today Fiorentina-Napoli 0-0 - Live
-
Federal Regulators Approve New Alzheimer's Blood Test
Federal regulators recently approved a new blood test for Alzheimer disease, expanding diagnostic options as health officials examine making new dementia drugs available on the National Health Service. Concurrently, a University of Sydney study found that 188 social media posts across Facebook, Instagram, and TikTok, reaching a combined audience exceeding 114 million followers, are spreading misleading claims that diverge from clinical recommendations regarding these blood tests. Additionally, researchers identified sex-specific biological aging clocks linked to Alzheimer progression.
Why it matters
The federal approval of the Alzheimer's blood test marks a significant step in neurological diagnostics, though misinformation online complicates public understanding. Health Secretary Yvette Cooper stated that authorities will review making new dementia treatments accessible on the NHS. Meanwhile, the House Ways and Means Committee advanced policies promoting better early detection screening for Alzheimer disease.
What is confirmed
- Federal regulators approved a new blood test for Alzheimer disease.
- A University of Sydney study examined 188 social media posts across Facebook, Instagram, and TikTok.
- Social media platforms spreading misleading claims about Alzheimer blood tests have a combined audience exceeding 114 million followers.
- Researchers identified sex-specific biological aging clocks linked to Alzheimer progression.
- Health Secretary Yvette Cooper stated that authorities will look at making new dementia drugs available on the NHS.
Still unconfirmed
- The House Ways and Means Committee advanced policies for better early detection screening for Alzheimer disease.
What to watch next
- Implementation of policies advancing early detection screening for Alzheimer disease by the Ways and Means Committee
- Further decisions regarding the availability of new dementia drugs on the NHS
confidence 100%Sources used for this update (8)
- www.newswise.com — Cancer Care Uses Biological Tests to Guide Treatment. Why Doesn't Psychiatry?
- www.mmm-online.com — Rx Rundown: Novo Nordisk, Roche, Johnson & Johnson and more
- www.wvnews.com — State residents to join Walk to End Alzheimer's events across nine communities this fall
- markets.ft.com — U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
- finance.yahoo.com — HOPE-Neuron Opens Investment Round to Fund First Human Trial of a Non-Drug ALS Treatment
- www.saltwire.com — 'It's like doing a bit of an archaeological dig': Vision loss can be written in your genes
- internationalfinance.com — The server rack that has to be fed every 3 days
- waysandmeans.house.gov — Ways & Means Committee Advances Policies Benefitting American Patients, Parents, Taxpayers, & Critical Supply Chains
-
FDA Approves New Blood Test for Alzheimer’s Disease
Federal regulators recently approved a new blood test for Alzheimer disease. Concurrently, a University of Sydney study of 188 social media posts across Facebook, Instagram, and TikTok found that platforms with a combined audience exceeding 114 million followers are spreading misleading claims regarding these blood tests that diverge from clinical recommendations. Researchers also identified sex-specific biological aging clocks linked to Alzheimer progression, while Health Secretary Yvette Cooper stated that authorities will look at making new dementia drugs available on the NHS.
Why it matters
Accurate tracking of cognitive decline requires distinguishing between verified clinical procedures and unverified claims circulating online. At the same time, researchers continue to link sex-specific biological aging clocks across organ systems to the progression from mild cognitive impairment to Alzheimer disease in both women and men.
What is confirmed
- Federal regulators recently approved a new blood test for Alzheimer disease.
- Researchers raised concerns that social media platforms are spreading misleading claims regarding Alzheimer disease blood tests that diverge from current clinical recommendations.
- A University of Sydney study analyzed 188 posts shared between March 2014 and May 2025 across Facebook, Instagram, and TikTok, originating from accounts with an audience exceeding 114 million followers.
- Brain aging clocks were linked to the progression from mild cognitive impairment to Alzheimer disease in both sexes.
Still unconfirmed
- New dementia drugs could become available on the NHS following comments from Health Secretary Yvette Cooper.
What to watch next
- Decisions regarding the availability of new dementia drugs on the NHS
- Further clinical updates on newly approved Alzheimer blood tests and biomarker combinations
confidence 95%Sources used for this update (3)
- inews.co.uk — New dementia drugs could become available on the NHS
- www.news-medical.net — Social Media Spreading Misleading Claims About Alzheimer’S Blood Tests, Study Finds
- www.news-medical.net — Sex-specific biological clocks reveal how aging differs across the body in women and men
-
Researchers Warn of Misleading Social Media Claims on Alzheimer Blood Tests
Researchers warn that social media platforms are spreading misleading claims regarding Alzheimer disease blood tests, diverging from current clinical recommendations. A University of Sydney study analyzed 188 posts shared between March 2014 and May 2025 across Facebook, Instagram, and TikTok, originating from accounts with a combined audience exceeding 114 million followers. Meanwhile, federal regulators recently approved a new blood test for Alzheimer disease, and a Columbia University study indicates that combining the p-tau217 biomarker with APOE4 genetic testing can estimate when symptoms will emerge in currently symptom-free individuals.
Why it matters
The rise of promotional content on social media follows the clinical introduction of Alzheimer blood tests, which have been permitted in Australia since July. Medical experts previously maintained that predictive testing tools were not yet ready for general use. At the same time, patients in the United Kingdom face continued barriers accessing breakthrough dementia treatments because the National Health Service is not yet ready to deliver them.
What is confirmed
- Researchers from the University of Sydney analyzed 188 posts shared between March 2014 and May 2025 on Facebook, Instagram, and TikTok about Alzheimer blood tests.
- The analyzed social media posts regarding Alzheimer blood tests came from accounts with a combined audience of more than 114 million followers.
- Alzheimer blood tests have been allowed in Australia since July.
- Federal regulators approved a new blood test for Alzheimer disease, adding to diagnostic tools available to clinicians.
Still unconfirmed
- Social media posts are actively promoting Alzheimer blood tests with claims that do not align with current clinical recommendations.
What to watch next
- Further publications analyzing the impact of social media misinformation on patient diagnostic decisions
- Updates on clinical adoption and regulatory guidelines for Alzheimer blood tests internationally
confidence 90%Sources used for this update (7)
- inews.co.uk — Anthony Scaramucci: Farage is a dumber version of Trump
- pancan.org — PanCAN Announces 2026 Research Grant Recipients
- www.newscientist.com — Xand van Tulleken on the 3 wellness trends to be most wary of
- www.quiverquant.com — Quiver News
- www.bostonglobe.com — Want to lower your risk of dementia? You don’t need to wait for a blood test.
- multiplesclerosisnewstoday.com — Plant extract shows neuroprotective effects in rat model of multiple sclerosis
- medicalxpress.com — Social media spreading misleading claims about Alzheimer's blood tests
-
New Testing Methods Aim to Predict Alzheimer's Symptoms
Federal regulators approved a new blood test for Alzheimer's disease, adding to diagnostic tools available to clinicians. A Columbia University study reports that combining the p-tau217 blood biomarker with APOE4 genetic testing can estimate when symptoms will emerge in people who are currently symptom-free. Previously, medical experts maintained that predictive testing tools were not ready for general use. Meanwhile, patients in the United Kingdom face continued barriers accessing breakthrough dementia treatments because the National Health Service is not yet ready to deliver them.
Why it matters
Diagnostic tools for neurodegenerative conditions are advancing rapidly, shifting the focus toward early risk identification. However, the availability of advanced screening methods contrasts with ongoing delivery bottlenecks in public health systems. This gap creates challenges for patients seeking access to newly developed therapeutic options.
What is confirmed
- A Columbia University study found that combining the p-tau217 blood biomarker with APOE4 genetic testing may estimate when Alzheimer's symptoms will emerge in symptom-free people.
What to watch next
- Broader clinical adoption of the newly approved blood test by healthcare providers
- Policy updates regarding National Health Service readiness for dementia treatments in the United Kingdom
confidence 100%Sources used for this update (5)
- www.ibtimes.com.au — New Blood and Gene Test Combo Can Predict Alzheimer's Symptoms Years Before They Appear, Study Finds
- www.psychologytoday.com — Separating Fact from Fiction in Alzheimer's Treatment
- jen.jiji.com — Al Bano performs in Tel Aviv, controversy erupts: "In a divided world, music continues to be a bridge"
- www.yahoo.com — Dementia drugs made in UK but denied on NHS
- www.pressherald.com — 6 things you need to know about this year’s Dempsey Challenge in Lewiston
-
New Blood Tests Simplify Alzheimer's Diagnosis
New blood tests offer a simpler way to diagnose Alzheimer's disease, though experts caution these tools are not suitable for everyone. While blood tests might preview risk or identify potential, doctors previously maintained that predictive tools are not yet ready for general use. In the United Kingdom, experts warned that patients risk missing out on breakthrough Alzheimer's treatments because the National Health Service is not ready to deliver them. Meanwhile, individuals can take steps now to lower later-in-life dementia risk without needing a blood test.
Why it matters
Diagnosing Alzheimer's pathology historically relied on expensive PET scans or specialized evaluations. Recent research from Columbia University indicated that combining a blood test with a genetic test provides a more useful estimate of when symptoms will first appear in high-risk individuals compared to using either test alone. This follows the FDA clearance of the Roche Elecsys pTau217 blood test, which was intended to reduce reliance on PET scans.
What is confirmed
- New blood tests offer a simpler way to help diagnose Alzheimer's disease.
- Experts warned that patients risk missing out on breakthrough Alzheimer's treatments because the NHS is not ready to deliver them.
Still unconfirmed
- Anyone can take steps now to lower their risk of later-in-life dementia without taking a test.
What to watch next
- Wider clinical adoption and readiness of the NHS to deliver breakthrough treatments
- Upcoming educational events such as the Alzheimer's Foundation of America conference on September 16 in New Hampshire
confidence 90%Sources used for this update (9)
- www.timesleader.com — Want to lower your risk of dementia? It doesn’t involve a blood test
- malaysia.news.yahoo.com — NHS ‘not ready’ to deliver breakthrough Alzheimer’s treatments
- www.baltimoresun.com — New blood tests offer a simpler way to help diagnose Alzheimer’s
- www.bostonherald.com — Want to lower your risk of dementia? It doesn’t involve a blood test
- www.nhbr.com — Alzheimer’s Foundation of America bringing free educational conference to New Hampshire on Sept. 16
- www.pharmexec.com — Wendy Short Bartie: Reputation as Currency
- blackpressusa.com — BOOK REVIEW — Curved Air: A Biography of Sickle Cell Anemia and the Quest to Cure the First Molecular Disease
- finance.yahoo.com — BRAINBox and Prolight sign supply agreement for concussion tests
- en.sedaily.com — Painless Lump on Neck May Signal Lymphoma, Doctor Warns
-
Columbia University study suggests combined blood and genetic tests predict Alzheimer's
Researchers at Columbia University found that combining a blood test with a genetic test provides a more useful estimate of when Alzheimer's symptoms will first appear in high-risk individuals than using either test alone. While Labcorp has unveiled a blood test to identify Alzheimer's potential, some doctors maintain that these predictive tools are not yet ready for general use. This development follows previous FDA clearance of the Roche Elecsys pTau217 blood test, which aimed to reduce reliance on expensive PET scans for diagnosing Alzheimer's pathology.
Why it matters
The medical field is shifting toward blood-based biomarkers to detect complex diseases before symptoms emerge. This approach aims to replace invasive imaging and allow for earlier intervention. Current efforts include clinical trials testing if existing drugs can help patients before they show cognitive decline.
What is confirmed
- The FDA previously cleared the Roche Elecsys pTau217 blood test for Alzheimer's pathology.
Still unconfirmed
- Some doctors believe new blood tests that predict Alzheimer's years before symptoms begin are not yet ready.
What to watch next
- Clinical trial results regarding the use of existing drugs to prevent cognitive decline in Alzheimer's patients.
- FDA regulatory decisions on combined blood and genetic testing protocols for symptom prediction.
confidence 70%Sources used for this update (6)
- jen.jiji.com — Mongolia and France agree to strengthen school lunch program
- www.courant.com — Want to lower your risk of dementia? It doesn’t involve a blood test
- www.dailymail.com — Six drugs that could TRANSFORM Parkinson's treatment
- www.postandcourier.com — ‘This is something I can do.’ Charleston man fights to be part of cure for Alzheimer's disease.
- knowridge.com — Two Tests May Show When Alzheimer’s Symptoms Will Begin
- journalnow.com — Labcorp unveils blood test identify potential for Alzheimer's disease in patients
-
FDA Approves Blood-Guided Treatment for Advanced Breast Cancer
The FDA approved a new pill for advanced breast cancer that utilizes a blood test to detect treatment resistance before imaging scans can identify it. This follows previous regulatory clearance of the Roche Elecsys pTau217 blood test for Alzheimer's pathology and the use of screening algorithms to reduce PET scans in clinical trials. These developments signal a shift toward blood-based biomarkers to guide treatment and diagnosis for complex diseases, reducing reliance on invasive or expensive imaging while potentially extending the time before a patient's condition worsens.
Why it matters
Clinicians are increasingly using blood-based biomarkers to rule in or out neurological and oncological conditions early. This approach aims to streamline patient recruitment for trials and personalize drug administration based on real-time biological data.
What is confirmed
- The FDA cleared Roche's Elecsys pTau217 blood test to identify amyloid pathology in adults with cognitive impairment.
- A blood-based screening algorithm has reduced the number of unnecessary PET scans used to recruit Alzheimer's patients for clinical trials.
Still unconfirmed
- A blood test for breast cancer can spot resistance before a scan does.
What to watch next
- Further FDA approvals of blood-based biomarkers for other neurodegenerative diseases.
confidence 90%Sources used for this update (8)
- jen.jiji.com — AI-designed drug may slow signs of human aging
- jen.jiji.com — Kazakh president approves new regulations for Security Council and its Office
- www.pharmabiz.com — US FDA grants Priority Review status to Roche’s sBLA for Enspryng for MOGAD, an autoimmune disease with no approved treatments
- rocklandtimes.com — September Is a Good Month to Talk About Memory
- jen.jiji.com — Africa CDC warns Ebola spreading beyond eastern Congo epicentre
- www.rttnews.com — New FDA Drug Approvals - August 2026
- jen.jiji.com — Robot conductor leads Kurmangazy Orchestra’s 93rd concert season opener
- www.yahoo.com — New drug for advanced breast cancer guided by blood test approved by FDA
-
New Screening Tool Cuts Unnecessary Alzheimer PET Scans
A blood-based screening algorithm has dramatically reduced the number of unnecessary PET scans required to recruit patients at risk of Alzheimer's disease for clinical trials. Published in the journal Alzheimer's and Dementia, research from scientists at the Keck School of Medicine of USC shows that this algorithmic approach improves how patients are screened. This breakthrough follows the FDA clearance of Roche's Elecsys pTau217 blood test, which helps clinicians identify amyloid pathology in adults with cognitive impairment and rule the condition in or out early.
Why it matters
Diagnosing Alzheimer's disease before significant brain damage occurs remains a central hurdle for clinical trials and patient care. Traditional recruitment methods often rely on expensive and invasive procedures like PET scans. Integrating blood-based screening algorithms and newly cleared diagnostics aims to streamline trial enrollment and patient management significantly.
What is confirmed
- A new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial.
- The research was conducted by scientists at the Keck School of Medicine of USC and published in the journal Alzheimer's & Dementia.
What to watch next
- Adoption rates of the new blood-based screening algorithm in other clinical trials
- Further peer-reviewed validation of the USC Keck School of Medicine screening tool
confidence 100%Sources used for this update (8)
- www.today.com — Is There a Summer COVID Surge? With Cases Rising in Nearly Every State, Watch for These Symptoms
- jen.jiji.com — Kazakhstan's bank assets rise to 75.6 trillion tenge
- medicalxpress.com — Algorithmic tool may improve screening of patients for an Alzheimer's clinical trial
- jen.jiji.com — Kazakhstan, Switzerland hold 7th round of political consultations
- www.news-medical.net — New blood screening algorithm reduces unnecessary Alzheimer's PET scans
- www.miragenews.com — Test Combo Predicts Alzheimer's Years in Advance
- www.insideprecisionmedicine.com — Palani Kumaresan: Roche Diagnostics Is Ramping Up—Should Illumina Be Worried?
- www.finanznachrichten.de — F. Hoffmann-La Roche Ltd: U.S. FDA grants Priority Review for Roche's Enspryng for MOGAD, an autoimmune disease with no approved treatments
-
FDA approves Roche blood test for Alzheimer's pathology
The FDA has cleared the Elecsys pTau217 blood test from Roche, providing clinicians a less invasive method to identify amyloid pathology in adults with cognitive impairment. This diagnostic tool helps rule in or rule out Alzheimer's disease before significant brain damage occurs. To build on this diagnostic capability, Roche has launched the PrevenTRON trial in the UK. This study tests the drug trontinemab on patients with preclinical Alzheimer's disease to advance treatment options for those in the earliest stages of the condition.
Why it matters
Early detection of amyloid pathology is critical for initiating interventions before irreversible neurological decline. The combination of a blood-based diagnostic and targeted therapeutics represents a shift toward preclinical management of the disease.
What is confirmed
- The FDA cleared the Elecsys pTau217 blood test to identify amyloid pathology in adults with cognitive impairment.
- Roche launched the PrevenTRON trial in the UK to test trontinemab on patients with preclinical Alzheimer's disease.
What to watch next
- Results from the PrevenTRON trial regarding trontinemab efficacy
- Further FDA clearances for preclinical Alzheimer's therapeutics
confidence 100%Sources used for this update (7)
- inews.co.uk — HMRC delays cost me £323 – hundreds of thousands of parents are at risk
- www.nationalgeographic.com — Why GLP-1s Could Be an Anti-Aging Breakthrough
- www.theglobeandmail.com — A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
- finance.yahoo.com — Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
- finance.yahoo.com — IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival ...
- www.thestar.com.my — Early data indicates an AI-generated drug could slow ageing
- muddyriversports.com — VapoCept Reviews and Complaints 2026 – Legit Cognitive Support Formula or Overhyped? What the Research Actually Shows
-
Roche begins European trials for Alzheimer's drug trontinemab
Roche has launched the PrevenTRON trial in the UK to test its Brainshuttle drug trontinemab on patients with preclinical Alzheimer's disease. This therapeutic push follows the FDA's clearance of Roche's Elecsys pTau217 blood test, which allows clinicians to identify amyloid pathology in adults with cognitive impairment. While the blood test provides a less invasive way to rule in or rule out the disease before significant brain damage occurs, the trontinemab trial seeks to advance treatment options for those in the earliest stages of the condition.
Why it matters
Early detection of amyloidosis traditionally requires expensive or inaccessible procedures. Moving toward blood-based diagnostics and preclinical drug trials aims to treat the disease before severe cognitive decline.
What is confirmed
- The PrevenTRON trial of Roche's Brainshuttle drug trontinemab has begun in the UK for preclinical Alzheimer's disease.
- The FDA cleared Roche Holding's Elecsys pTau217 blood test to help clinicians rule in and rule out amyloid pathology in Alzheimer's disease.
What to watch next
- Results from the PrevenTRON trial regarding trontinemab efficacy
- FDA decisions on additional biomarkers for dementia diagnosis
confidence 100%Sources used for this update (7)
- medicalxpress.com — Understudied gut fungus may help repair radiation-damaged DNA and limit intestinal injury
- www.unilad.com — New research reveals futuristic side effect Ozempic could have and it's more than just weight loss
- pharmaphorum.com — Major trial of Roche Alzheimer's drug kicks off in Europe
- www.alzheimersresearchuk.org — How Alzheimer’s Research UK helped develop blood tests for Alzheimer’s
- www.dailymail.com — Experimental cancer drug could stop osteoporosis and help women stay slim after menopause
- www.news-medical.net — Experimental cancer drug could protect against osteoporosis and weight gain
- www.insidermonkey.com — Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
-
Roche Wins FDA Clearance for Alzheimer's Blood Test
The U.S. Food and Drug Administration has cleared Roche Holding's Elecsys pTau217 blood test as the first single biomarker assay designed to help clinicians both rule in and rule out amyloid pathology in Alzheimer's disease. The diagnostic tool is intended to support physicians in evaluating adult patients showing symptoms of cognitive impairment earlier in the condition's progression. Traditional procedures for identifying amyloidosis are often expensive or difficult to access, making this simpler and less invasive option a significant shift for clinical access. The test functions as an early evaluation aid before significant brain damage occurs.
Why it matters
Alzheimer's disease diagnostics have historically relied on expensive or difficult-to-access procedures to confirm or rule out amyloidosis. Introducing a single biomarker blood test allows clinicians to evaluate patients more easily at earlier stages of cognitive impairment. Roche developed the Elecsys pTau217 assay to assist physicians in managing patient evaluation workflows.
What is confirmed
- The FDA cleared Roche Holding's Elecsys pTau217 blood test to help physicians evaluate patients for Alzheimer's disease.
- The Elecsys pTau217 test is the first single biomarker assay to help both rule in and rule out amyloid pathology in Alzheimer's disease.
- The test is intended to support clinicians in earlier evaluation of adult patients showing symptoms of cognitive impairment.
What to watch next
- Commercial rollout and pricing announcements for the Elecsys pTau217 test
- Adoption rates among clinical practices and memory centers
confidence 100%Sources used for this update (10)
- jen.jiji.com — Popular weight-loss drug shows anti-aging effects
- jen.jiji.com — Almaty oncology center introduces robotic pharmacy system
- finance.yahoo.com — Roche Holding (SWX:ROP) Received FDA Clearance For An Alzheimer’s Blood Test
- medicaldialogues.in — FDA Grants Accelerated Approval to a New Breast Cancer Treatment
- www.sciencedaily.com — A simple blood test could detect multiple cancers and reveal where they started
- www.news-medical.net — New prostate cancer screening advances improve early detection
- jen.jiji.com — Kazakhstan expands exploration plans with up to 200 new wells
- jen.jiji.com — Death toll from mudslide in Nepal rises to 1,355, nearly 5,000 missing
- www.news-medical.net — Genetic COPD risk emerges early with higher air pollution
- finance.yahoo.com — Isomab presents landmark data study supporting safety of angiogenic approaches in coronary artery disease
-
FDA clears Elecsys pTau217 blood test for Alzheimer's assessment
The FDA has cleared Elecsys pTau217, a blood test developed by Roche Holding AG and Eli Lilly and Company to help physicians evaluate patients for Alzheimer's disease. The test offers a simpler, less invasive alternative to traditional diagnostic procedures that are often expensive or difficult to access. It is available to adults aged 40 and older who show symptoms of cognitive impairment, allowing clinicians to confirm or rule out amyloidosis early in the disease's progression before significant brain damage occurs.
Why it matters
Traditional Alzheimer's diagnostics often require invasive or costly procedures. Early detection is critical because clinical symptoms typically emerge only after substantial neurological damage has already taken place.
What is confirmed
- The FDA cleared the Elecsys pTau217 blood test to help identify Alzheimer's-related brain changes.
- Roche Holding AG and Eli Lilly and Company developed the blood test.
- The test is for adults 40 and older with symptoms of cognitive impairment.
- The test provides a less invasive alternative to traditional diagnostics that are often expensive or difficult to access.
What to watch next
- Clinical adoption rates of Elecsys pTau217 in primary care settings
- Availability of the test across different healthcare providers
confidence 100%Sources used for this update (5)
- finance.yahoo.com — Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
- www.bostonglobe.com — Alzheimer’s patients deserve to know their diagnosis
- www.news-medical.net — ART-conceived children show reassuring long-term health outcomes
- knowridge.com — Early Warning Signs of Pancreatic Cancer You Should Never Miss
- www.yahoo.com — NHS trust joins Alzheimer's prevention drug trial
-
FDA Clears Blood Test for Alzheimer Disease Diagnosis
The FDA approved a blood test for Alzheimer disease available to adults aged 40 and older showing symptoms of cognitive impairment. This test provides a less invasive and more accessible alternative to traditional diagnostic procedures that are often expensive or difficult to access. The test allows clinicians to confirm or rule out amyloidosis early in the disease progression, which is critical because symptoms typically appear after significant brain damage has occurred.
Why it matters
Alzheimer's is a brain disorder where early detection is difficult. Previous diagnostic methods relied on invasive or costly procedures. This new tool supports early intervention as diagnoses rise among people in their 50s and 60s.
What is confirmed
- The FDA approved a blood test to diagnose Alzheimer disease.
- Adults aged 40 years and older with symptoms of cognitive impairment may qualify for the blood test.
Still unconfirmed
- Diagnoses of dementia are rising in people in their 50s and 60s.
What to watch next
- Clinical trial results for BPN14770 regarding memory loss and nerve damage.
confidence 90%Sources used for this update (6)
- www.ynetnews.com — Dementia doesn’t always begin with memory loss: early warning signs to watch for
- www.aol.com — ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
- www.neurologyadvisor.com — FDA Clears Blood Test for Alzheimer Disease
- www.wamc.org — Health Your Self: Losing it - or not
- www.insidermonkey.com — Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
- www.raps.org — This Week at FDA: Foreign clinical trial scrutiny, botanical drugs, and an EUA declaration
-
FDA Approves New Blood Test For Alzheimer’s Disease
The US Food and Drug Administration has approved the first-ever blood test to diagnose Alzheimer's disease early, providing a way to confirm or rule out amyloidosis. Alzheimer's is a brain disorder with symptoms appearing after much of the damage is done. Additional research indicates that a drug called BPN14770 can help treat memory loss and nerve damage, while another study revealed that a process called axon myelination is significantly disrupted in patients. Meanwhile, an Alzheimer's trial by Annovis surpassed its enrollment goal by signing up 850 patients.
Why it matters
Early detection remains critical for brain disorders because current treatments work best in the early stages. Traditional symptoms often manifest long after significant neural damage has already occurred. Diagnostic tools such as blood tests aim to streamline the identification process for clinicians and patients.
What is confirmed
- The US Food and Drug Administration approved a new test to confirm or rule out the presence of amyloidosis and diagnose Alzheimer's disease early.
Still unconfirmed
- A drug called BPN14770 can help treat memory loss and nerve damage according to research published in the Journal of Pharmacology and Experimental Therapeutics.
- Axon myelination is significantly disrupted in patients with Alzheimer's according to a study published in the journal Nature.
- An Alzheimer's trial by Annovis enrolled 850 patients, exceeding its target of 760.
- Childhood vaccination rates are declining throughout the United States.
What to watch next
- Broad commercial rollout and pricing details for the newly approved blood test
- Further clinical trial results from Annovis regarding its Alzheimer's treatment pill
- Peer-reviewed findings on drug treatments like BPN14770 and axon myelination
confidence 100%Sources used for this update (4)
- sg.news.yahoo.com — ‘Setup For A Disaster’: Pediatricians Predict Will Happen If Vaccination Rates Continue To Fall
- en.ilsole24ore.com — Alzheimer’s: a new ‘two-in-one’ blood test to detect the disease is on the way
- Longevity.Technology — Annovis sails past enrollment goal on Alzheimer’s
- www.thehealthsite.com — Alzheimer's Blood Test
-
FDA Approves Elecsys pTau-217 Blood Test for Alzheimer's
The US FDA has approved the Elecsys pTau-217 blood test for Alzheimer's disease, developed by Roche and Eli Lilly. The test, available for adults 55 and older with cognitive decline, offers a less invasive diagnostic alternative. Labcorp will provide the test in primary and specialty care settings. Early detection is crucial as current FDA-approved treatments are most effective in the disease's early stages.
Why it matters
Alzheimer's disease is a progressive neurological disorder with no cure, but early detection can significantly impact treatment effectiveness. Traditional diagnostic procedures can be invasive and costly. The approval of this blood test marks a significant advancement in Alzheimer's diagnosis and management.
What is confirmed
- The Elecsys pTau-217 blood test was developed in collaboration by Roche and Eli Lilly.
- The test is intended for adults 55 and older with signs or symptoms of cognitive decline.
- Labcorp will provide the Elecsys pTau-217 blood test in primary and specialty care settings.
What to watch next
- Availability and pricing of the Elecsys pTau-217 blood test
- Impact on Alzheimer's disease diagnosis and treatment rates
- Potential updates on the test's effectiveness and limitations
confidence 100%Sources used for this update (6)
- jen.jiji.com — Imola, man found dead at home covered in blood: wife arrested
- www.medicalbrief.co.za — First single-biomarker blood test for Alzheimer's approved
- www.psychologytoday.com — Can a Blood Test Predict Your Risk of Alzheimer’s Disease?
- jen.jiji.com — Kazakhstan’s top short-track athlete Abzal Azhgaliyev announces retirement
- www.news-medical.net — New app aims to boost prostate cancer screening among Black men
- www.nbcnews.com — Doctors fill CDC guidance void with new vaccine recommendations
-
FDA-approved Alzheimer's blood test available via Labcorp
The US FDA has approved Elecsys pTau-217, a blood test for Alzheimer's disease developed by Roche and Eli Lilly. Labcorp will provide the test for adults 55 and older experiencing cognitive decline in primary and specialty care settings. This diagnostic tool offers a less invasive alternative to traditional procedures. Early detection is essential because current FDA-approved prescriptions are most effective when used during the earliest stages of the disease.
Why it matters
Traditional Alzheimer's diagnostics often involve more invasive methods. Rapid identification allows patients to begin treatment during the window of maximum efficacy.
What is confirmed
- The FDA approved the Elecsys pTau-217 blood test for Alzheimer's disease.
- Roche and Eli Lilly developed the Elecsys pTau-217 test.
- Labcorp will provide the test for adults aged 55 and older with cognitive decline.
What to watch next
- Clinical data on the impact of early detection via pTau-217 on patient outcomes
- Expansion of test availability to additional laboratory providers
confidence 100%Sources used for this update (6)
- jen.jiji.com — Rett Syndrome, EU approval for neurobehavioral symptom treatment
- jen.jiji.com — 6 killed in road accident on Saryozek-Koktal highway
- www.news-medical.net — New method based on human blood simplifies mRNA drug development
- jen.jiji.com — Kazakhstan to simplify companies' access to stock market
- jen.jiji.com — Inter, Ausilio will not renew contract: leaves club after 28 years
- www.dailymail.com — Trial for autoimmune disease treatment urgently halted after multiple participants die
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community